Wall, Kathryn M.
Dell, Jaclyn
Lowell, Amanda
Potenza, Marc N.
Mayes, Linda C.
Rutherford, Helena J. V. http://orcid.org/0000-0001-8680-1535
Funding for this research was provided by:
National Institute on Drug Abuse (R01 DA026437-08)
Article History
Accepted: 18 October 2022
First Online: 15 November 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Yale University Human Investigation Committee.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.
: Kathryn M. Wall, Jaclyn Dell, Amanda Lowell, Linda C. Mayes, and Helena J. V. Rutherford declare no conflicts of interest. Marc N. Potenza has consulted for and advised Opiant Pharmaceuticals, Idorsia Pharmaceuticals, AXA, Game Day Data and the Addiction Policy Forum; has been involved in a patent application with Yale University and Novartis; has received research support from the Mohegan Sun Casino and Connecticut Council on Problem Gambling; has participated in surveys, mailings, or telephone consultations related to drug addiction, impulse control disorders, or other health topics; and has consulted for law offices and gambling entities on issues related to impulse control or addictive disorders.
: The views presented in this manuscript are those of the authors and do not necessarily reflect those of the funding agencies.